Assessing switching to long-acting buprenorphine injection in jail
Part of Mental health clinical trials.
This study tests whether switching from daily buprenorphine/naloxone (Suboxone) to a long-acting injectable buprenorphine (XRB) is safe and effective for men who are unsentenced and in jail for at least 4 days. It aims to see if the injection can help continue treatment without needing daily medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man currently in jail (unsentenced) and expected to stay at least 4 days.
- You must be able to read and understand English and give your permission to join the study.
- You are already taking buprenorphine/naloxone (a medication for opioid use disorder) for at least 3 days before starting the study.
- You are willing to be randomly assigned to switch to a long-acting injectable form of buprenorphine (called XRB) while you are in jail.
- You do not have any allergy or medical condition that would make taking buprenorphine/naloxone unsafe, and you do not have chronic pain that needs treatment with opioid pain medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a once-monthly injection of buprenorphine (called extended-release buprenorphine, or XR-B) works well for people in prison who are already in a medication program for opioid use disorder. It looks at preferences and outcomes in the last months before release.
This trial tests a long-acting, once-monthly injection of buprenorphine (BRIXADI) given from a mobile pharmacy clinic. It aims to see if this approach is acceptable and practical for people with opioid use disorder, making treatment more accessible.
This trial tests different doses of buprenorphine to find the safest and most effective one for treating opioid use disorder and preventing overdose. It is for people who have used fentanyl and are starting or continuing buprenorphine treatment.
This trial offers buprenorphine (a medication for opioid use disorder) to people in jail who are soon to be released. It helps you start treatment while incarcerated and continue it after you return to the community, aiming to reduce overdose and improve recovery.
This trial compares taking buprenorphine by mouth versus as an injection for opioid use disorder. It aims to see which option helps people stay on treatment and reduces opioid use over about a year.
This study tests a behavioral support program designed to help people newly starting buprenorphine treatment for opioid use disorder stay engaged with their care. If you've recently started buprenorphine or just been released from incarceration and are beginning treatment, this trial may help you maintain consistent medication use and reduce the risk of relapse.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.